Sign in
Taking people in United StatesPhase 2

BCAAs in Concussion 3.0

Key facts

Who runs it
Akiva Cohen
Where
Havertown, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
5 Aug 2026
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BCAA
  • Placebo
Record updated
3 September 2026

Who can take part

Age
11 years to 23 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Males and females,11 - 23 years of age
  • Weigh at least 40kg
  • Meeting concussion criteria for the American Congress of Rehabilitative Medicine; One or more clinical signs or two or more acute symptoms with at least one VVE abnormality
  • Present within 4 days of injury
  • Post-menarchal females must have a negative urine pregnancy test
  • Informed consent by the participant, or for participants <18 years old both informed consent by a parent/guardian and child assent

Who cannot take part

  • Prior concussion or TBI within 90 days
  • Any investigational drug use within 30 days prior to enrollment
  • Known history of maple syrup urine disease or known family history of maple syrup urine disease
  • Evidence of moderate or severe TBI, including GCS <13, TBI requiring hospital admission, or TBI requiring neurosurgical intervention
  • Participants who are pregnant, planning on becoming pregnant during the study duration, or breastfeeding
  • Non-English speaking participants or parent/guardian

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 11 and 23 years old?

This trial is currently available in United States.

  • Children's Hospital of PhiladelphiaHavertown, United StatesContact: Daniel Corwin, MDTaking people

About the trial

What the trial wants to find out

This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.

The 2 groups in the trial

  • Drug: Branched Chain Amino AcidsTreatment being tested

    The three BCAAs will be combined together into a powder formulation.

    Treatment: BCAA

  • PlaceboPlacebo, for comparison

    The placebo formulation will have similar taste, texture, consistency and appearance as the BCAA formulation.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
HIT HEADS 3.0: Head Injury Treatment: A Randomized, Placebo-controlled, Double-blinded, Therapeutic Clinical Trial of Branched Chain Amino Acids (BCAAs) in the Treatment of Concussion
Criteria questions
Built from NCT07670195, who can take part
Record updated
3 September 2026